High-throughput rational design of the remdesivir binding site in the RdRp of SARS-CoV-2: implications for potential resistance

Summary: The use of remdesivir to treat COVID-19 will likely continue before clinical trials are completed. Due to the lengthening pandemic and evolving nature of the virus, predicting potential residues prone to mutation is crucial for the management of remdesivir resistance. Using a rational ligan...

Full description

Bibliographic Details
Main Authors: Aditya K. Padhi, Rohit Shukla, Prakash Saudagar, Timir Tripathi
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:iScience
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004220311895